Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC)
A new approach to diagnosing kidney cancer, called the Cambridge [...]
Quit smoking this New Year for a healthier you!
Smoking is one of the risk factors for the development [...]
89Zr-girentuximab PET/CT effect on management of patients with kidney masses
Researchers are looking for better ways to diagnose kidney cancer. Currently, diagnosis is [...]
Five year follow-up of belzutifan for VHL disease
VHL disease is a hereditary disease that affects many organs of [...]
Five-year follow-up results of adjuvant pembrolizumab for kidney cancer
Surgery (partial or radical nephrectomy) is the standard of care for [...]
Stopping treatment with immunotherapy after immune-related side effects seems to have favourable outcomes
A recent study wanted to find out what happens to [...]
The role of nutrition in kidney cancer care
A great presentation at the 2025 International Kidney Cancer Symposium [...]
Belzutifan plus lenvatinib show promise as a second-line treatment for advanced kidney cancer
A recent study, called the Phase 3 LITESPARK-011 trial, looked [...]
Pembrolizumab plus belzutifan combination shows promise as an adjuvant treatment for kidney cancer
A large phase 3 clinical trial tested two medicines, pembrolizumab [...]
Kidney Cancer Highlights from ESMO 2025
This year’s European Society for Medical Oncology (ESMO) Congress was [...]
